The increasing frequency of decreased expression of Beclin 1 in normal ovarian tissues (8.3%), benign cystadenomas (15.4%), borderline tumors (20.0%), and ovarian carcinomas (55.6%) was statistically significant (P<0.0001, Table S1). This evidence concerns the gene BECN1 and cystadenoma.